Lev Gerlovin discuss the challenges posed to the biopharma business model by revolutionary, but prohibitively expensive, cell and gene therapies. To improve efficiencies and mitigate risk, drug developers now are looking at new options in stakeholder engagement and collaboration, as well as identifying new options for financing.
Read more here in The Pharma Letter Expert View.
The authors wish to acknowledge the contributions of Pascale Diesel, Stephanie Donahue, Walter Colasante, and Michael Krepps to this article.
